Organisation paid for research Program year 2025 Source: CMS Open Payments

University Physicians Inc

Neither a doctor nor a teaching hospital

Research payments

$29,499

18 payments

Through program year 2025, University Physicians Inc is reported as receiving $29,499 in research payments, across 18 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,836 4
2024 Research $7,583 5
2023 Research $2,613 2
2022 Research $1,588 2
2021 Research $4,440 2
2020 Research $640 2
2019 Research $3,800 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $9,100 5 payments
  2. Merck Sharp & Dohme Corporation $8,269 2 payments
  3. United Therapeutics Corporation $4,440 5 payments
  4. Eli Lilly and Company $3,800 1 payment
  5. Genentech, Inc. $1,650 2 payments
  6. Roche Products Limited $1,041 1 payment
  7. QED Therapeutics, Inc. $800 1 payment
  8. Novartis Pharmaceuticals Corporation $400 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. STUDY NAME#Translational Metrics Related to Orexins and Insomnia# Toward Assessing Integrity of Sleep's Neuroprotective Functions from a Single EEG Channel of Surface EEG $4,174 1 payment
  2. STUDY NAME#Translational Metrics Related to Orexins and Insomnia# Toward Assessing Integrity of Sleeps Neuroprotective Functions from a Single EEG Channel of Surface EEG $4,095 1 payment
  3. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $3,800 3 payments
  4. P3 KRd QW vs BIW Dosing Comparison in RRMM (A.R.R.O.W. 2) $3,640 1 payment
  5. A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer $2,698 1 payment
  6. Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma $1,650 2 payments
  7. Paediatric PK Study in Multiple Sclerosis Patients $1,041 1 payment
  8. A Randomized, Double-Blind Study to compare the Pharmacokinetics between ABP?234 and Keytruda® (Pembrolizumab) in Subjects with Early-Stage Non-squamous Non-Small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy $975 1 payment
  9. ABP 234 P3 Marigold Study PK SS/CCS in Advanced or Metastatic Non-Squamous NSCLC $975 1 payment
  10. Early-stage Non-squamous NSCLC; PK Similarity $813 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $800 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record